Evidence map›Paper›PMID 35087641›Full record

ArticleJournal of oral microbiology2022

Cetylpyridinium chloride promotes disaggregation of SARS-CoV-2 virus-like particles.

Manuel Bañó-Polo, Luis Martínez-Gil, Manuel M Sánchez Del Pino, Alberto Massoli, Ismael Mingarro, Rubén Léon, Maria Jesus Garcia-Murria

Open access · goldAbstract read
In one paragraph

Article in Journal of oral microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Antimicrobial cetylpyridinium chloride causes functional inhibition of mitochondria as potently as canonical mitotoxicants, nanostructural disruption of mitochondria, and mitochondrial CaFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2024
    Article
  6. Article
  7. Article
  8. SARS-CoV-2 virus-like-particlesNanoscale advances · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Manuel Bañó-PoloDepartment of Microbiology. Dentaid Research Center, Cerdanyola del Vallès, Barcelona, Spain.ORCID https://orcid.org/0000-0002-4840-4480
Luis Martínez-GilDepartment of Biochemistry and Molecular Biology, Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Valencia, Spain.ORCID https://orcid.org/0000-0002-9076-7760
Manuel M Sánchez Del PinoDepartment of Biochemistry and Molecular Biology, Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Valencia, Spain.ORCID https://orcid.org/0000-0001-9696-7600
Alberto MassoliDepartment of Microbiology. Dentaid Research Center, Cerdanyola del Vallès, Barcelona, Spain.
Ismael MingarroDepartment of Biochemistry and Molecular Biology, Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Valencia, Spain.ORCID https://orcid.org/0000-0002-1910-1229
Rubén LéonDepartment of Microbiology. Dentaid Research Center, Cerdanyola del Vallès, Barcelona, Spain.ORCID https://orcid.org/0000-0001-6400-4906
Maria Jesus Garcia-MurriaDepartment of Biochemistry and Molecular Biology, Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Valencia, Spain.ORCID https://orcid.org/0000-0002-8396-0335
Universitat de València · ESDentaid (Spain) · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSARS-CoV-2 is continuously disseminating worldwide. The development of strategies to break transmission is mandatory. AIM OF THE STUDY: To investigate the potential of cetylpyridinium chloride (CPC) as a viral inhibitor.

methodsSARS-CoV-2 Virus Like-Particles (VLPs) were incubated with CPC, a potent surfactant routinely included in mouthwash preparations.

resultsConcentrations of 0.05% CPC (w/v) commonly used in mouthwash preparations are sufficient to promote the rupture of SARS-CoV-2 VLP membranes.

conclusionIncluding CPC in mouthwashes could be a prophylactic strategy to keep SARS-CoV-2 from spreading.

Indexed as

cetylpyridinium chloridemembrane disaggregationSARS-CoV-2virologyvirus-like particles

Identifiers

PMID35087641
PMCPMC8788378
OpenAlexW4206899735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.